BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18269779)

  • 1. Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer.
    Ignatiadis M; Perraki M; Apostolaki S; Politaki E; Xenidis N; Kafousi M; Stathopoulos E; Lianidou E; Sotiriou C; Georgoulias V; Mavroudis D
    Clin Breast Cancer; 2007 Dec; 7(11):883-9. PubMed ID: 18269779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.
    Ignatiadis M; Kallergi G; Ntoulia M; Perraki M; Apostolaki S; Kafousi M; Chlouverakis G; Stathopoulos E; Lianidou E; Georgoulias V; Mavroudis D
    Clin Cancer Res; 2008 May; 14(9):2593-600. PubMed ID: 18451221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.
    Apostolaki S; Perraki M; Kallergi G; Kafousi M; Papadopoulos S; Kotsakis A; Pallis A; Xenidis N; Kalmanti L; Kalbakis K; Agelaki S; Kalykaki A; Stournaras C; Stathopoulos E; Georgoulias V; Mavroudis D
    Breast Cancer Res Treat; 2009 Oct; 117(3):525-34. PubMed ID: 19016323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.
    Xenidis N; Ignatiadis M; Apostolaki S; Perraki M; Kalbakis K; Agelaki S; Stathopoulos EN; Chlouverakis G; Lianidou E; Kakolyris S; Georgoulias V; Mavroudis D
    J Clin Oncol; 2009 May; 27(13):2177-84. PubMed ID: 19332733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers.
    Stathopoulou A; Mavroudis D; Perraki M; Apostolaki S; Vlachonikolis I; Lianidou E; Georgoulias V
    Anticancer Res; 2003; 23(2C):1883-90. PubMed ID: 12820473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of circulating cytokeratin-19 mRNA-positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer.
    Tryfonidis K; Kafousi M; Perraki M; Apostolaki S; Agelaki S; Georgoulias V; Stathopoulos E; Mavroudis D
    Clin Breast Cancer; 2014 Dec; 14(6):442-50. PubMed ID: 24958324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.
    Souglakos J; Vamvakas L; Apostolaki S; Perraki M; Saridaki Z; Kazakou I; Pallis A; Kouroussis C; Androulakis N; Kalbakis K; Millaki G; Mavroudis D; Georgoulias V
    Breast Cancer Res; 2006; 8(4):R36. PubMed ID: 16846533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.
    Bozionellou V; Mavroudis D; Perraki M; Papadopoulos S; Apostolaki S; Stathopoulos E; Stathopoulou A; Lianidou E; Georgoulias V
    Clin Cancer Res; 2004 Dec; 10(24):8185-94. PubMed ID: 15623593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status.
    Xu Y; Yao L; Li H; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Larsson O; Xie Y
    Breast Cancer Res Treat; 2006 May; 97(1):49-55. PubMed ID: 16319978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients.
    Masuda TA; Kataoka A; Ohno S; Murakami S; Mimori K; Utsunomiya T; Inoue H; Tsutsui S; Kinoshita J; Masuda N; Moriyama N; Mori M
    Int J Oncol; 2005 Mar; 26(3):721-30. PubMed ID: 15703829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
    Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
    Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
    Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B
    Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
    Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G
    Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the effect of surgery on the kinetics of circulating tumour cells in patients with operable breast cancer based on cytokeratin-19 mRNA detection.
    Daskalakis M; Mavroudis D; Sanidas E; Apostolaki S; Askoxylakis I; de Bree E; Georgoulias V; Melissas J
    Eur J Surg Oncol; 2011 May; 37(5):404-10. PubMed ID: 21376504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematogenous cytokeratin 20 mRNA detection has prognostic impact in oral squamous cell carcinoma: preliminary results.
    Toyoshima T; Vairaktaris E; Nkenke E; Schlegel KA; Neukam FW; Ries J
    Anticancer Res; 2009 Jan; 29(1):291-7. PubMed ID: 19331164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system.
    Stathopoulou A; Gizi A; Perraki M; Apostolaki S; Malamos N; Mavroudis D; Georgoulias V; Lianidou ES
    Clin Cancer Res; 2003 Nov; 9(14):5145-51. PubMed ID: 14613993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Application of suspension array assay to detect marker genes expression of circulating tumor cells for early prediction of breast cancer metastasis].
    Ke F; Wu JM; Yao JE; Bai YJ; Guo AL
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2257-61. PubMed ID: 18001545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [mRNA expression of CK19 and CEA in peripheral blood of patients with breast cancer detected by real-time quantitative PCR].
    Zheng HY; Chen Q; Ye YB; Huang WW
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(32):2267-70. PubMed ID: 19087676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection.
    Pinzani P; Salvadori B; Simi L; Bianchi S; Distante V; Cataliotti L; Pazzagli M; Orlando C
    Hum Pathol; 2006 Jun; 37(6):711-8. PubMed ID: 16733212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.